Skip to Main Content

A pivotal phase 2 clinical trial designed to help Celgene (CELG) and Bluebird Bio (BLUE) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week.

A listing for the clinical trial of the CAR-T therapy known as BB2121 was posted to the government’s website on Tuesday, with a planned start date of Dec. 11. Celgene licensed BB2121 from Bluebird and is the sponsor of the study, which the company is calling KarMMA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.